| Literature DB >> 18590336 |
Christopher S Burgey1, Daniel V Paone, Anthony W Shaw, James Z Deng, Diem N Nguyen, Craig M Potteiger, Samuel L Graham, Joseph P Vacca, Theresa M Williams.
Abstract
Two novel routes have been developed to the (3 R,6 S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one 2 of the CGRP receptor antagonist clinical candidate telcagepant (MK-0974, 1). The first employs a ring-closing metathesis of the styrene 7 as the key reaction, while the second makes use of a highly diastereoselective Hayashi-Miyaura Rh-catalyzed arylboronic acid addition to nitroalkene 16. The latter route has been implemented to produce multigram quantities of telcagepant for extensive preclinical evaluation.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18590336 DOI: 10.1021/ol8011524
Source DB: PubMed Journal: Org Lett ISSN: 1523-7052 Impact factor: 6.005